CDC7 and cancer: Selective inhibitors of CDC7 are being developed and trialed as anti-cancer therapeutics, with a number of candidate drugs undergoing clinical trials (Cheng et al., 2018, Gallagher et al., 2019, Huggett et al., 2016, Iwai et al., 2019, Koltun et al., 2012, Kurasawa et al., 2020, Sawa and Masai, 2009, Swords et al., 2010, Vanotti et al., 2008).